Drugs designed to precisely target cancers with specific genetic signatures have changed the course of disease for many patients. But for the majority, such drugs either don’t work because of innate resistance or they eventually stop working once the cancer develops new mutations that hamper their effectiveness.
Kinnate Biopharma, one of the biotechs working to tackle both problems, has raised $98 million to fund its plan to move two of its preclinical programs into the clinic next year. The Series C financing was led by RA Capital Management, a new backer.
The San Diego-based company, which has about 25 employees, is… Read more »
UNDERWRITERS AND PARTNERS